2/17/2016 | Creator: 36
Since its establishment, the EMRI has attained several prominent achievements which can be considered as unique in the field of research and treatment. They include:
Angipars: a Novel Herbal Medication for Diabetic Foot UlcerAngipars is a novel treatment option for patients with diabetic foot which is developed by the Endocrinology and Metabolism Research Institute. It is a plant derivative, and the active ingredients are assumed to be coumarin-like compounds that are abundant in the plant Melilotus Officialis. The plant is harvested, processed, and subsequently, the active ingredients are extracted and purified with the use of a complex technology so that to preserve therapeutic characteristics of the components. Angipars was introduced to the Iranian pharmacologic market in 2007, and only two years later, it had already been used for as many as 9000 diabetic Angipars is marketed in the form of packages containing both oral and topical forms of the medication. The course of treatment needs to be recommended by the physician, however, it is demonstrated that a minimum period of 6-week course of treatment results in significant increase in wound healing. It is noteworthy that several well-controlled clinical trials as well as numerous animal studies have been conducted to demonstrate the efficacy and safety of the medication.
Pancreatic Cell TransplantationAnother current option for patients with diabetes is to undergo a whole pancreas transplant, which is proved to be very successful in adults, but involves a major operation, making it unsuitable for children Following several years of research at EMRI, for the first time in our country, pancreatic cell transplantation has been successfully performed on two diabetic patients in September 2010. This operation followed the first phase of the pancreatic transplant project which was performed on animal models. It is expected that this novel method can decrease the burden of diabetes and its complications in adult diabetics, and, will eventually lead to more sustained results.
Stem Cells Treatment in DiabetesThe cell therapy technique allows surgeons to transplant islets, the clusters of pancreatic cells which produce insulin, into patients suffering from type I diabetes. Currently, patients need regular injections of insulin to overcome symptoms of diabetes. However, it does not necessarily prevent serious complications in later life such as blindness, kidney failure, and heart disease. In accordance with the EMRI vision, the institute considers the novel treatment option for some patients with diabetes.
Invention of a Device for the Detection of Sulfonylurea in the UrineResearchers of the Endocrinology and Metabolism Research Institute of Tehran University of Medical sciences have invented a device which is capable of detecting sulfonylurea in the urine. From two years ago, three different version of the device have been developed and successfully tested. Several validation tests and clinical trials have confirmed the efficacy of the new device.
Scientists in different fields such as chemistry, electronic engineering, software programming, and industrial design have contributed to this invention. This device will be introduced to the market for being used in the emergency wards and it is expected that it will play a very important role in differential diagnosis of comatose patients in whom intoxication with sulfonylurea is suspected.
Invention of a Portable Device for Pain-free Glucose Monitoring Using Saliva and TearsResearchers of the Center of Excellence in Electrochemistry (CEE) at the University of Tehran and Endocrinology and Metabolism Research Center (EMRC) of Tehran University of Medical Sciences have invented a portable device for measurement of glucose concentrations in saliva and tears.
The idea of invention of a device for non-invasive glucose measurement was conceived approximately 3 years ago with the view of eliminating pain in diabetic patients who have to test their blood sugar levels regularly. In March 2010, the first version of the device was launched and tested successfully. Shortly afterwards, the second, and then, the third versions of the device were developed. A prototype of the final version of the device is launched and is in the final testing stage. It is forecast that by the end of April 2014, the commercial version is launched and can be purchased by diabetic patients.